These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 12269359)
1. Report of the Task Force on the future of OTC drugs. Collins DE Food Drug Law J; 2000; 55(1):27-31. PubMed ID: 12269359 [No Abstract] [Full Text] [Related]
2. Direct-to-OTC marketing of drugs: possible approaches. Mahinka SP; Bierman ME Food Drug Law J; 1995; 50(1):49-63. PubMed ID: 10342985 [No Abstract] [Full Text] [Related]
3. A survey of developments in food and drug law from July 1998 to November 1999. Littlefield N; Hada NR Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348 [No Abstract] [Full Text] [Related]
4. Additional criteria and procedures for classifying over-the-counter drugs as generally recognized as safe and effective and not misbranded. Final rule. Food and Drug Administration, HHS Fed Regist; 2002 Jan; 67(15):3060-76. PubMed ID: 11820251 [TBL] [Abstract][Full Text] [Related]
5. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
7. Steps taken to lessen tampering with OTC drugs. FDA Drug Bull; 1983 Apr; 13(1):6. PubMed ID: 6852409 [No Abstract] [Full Text] [Related]
8. The debate continues on OTC switches. Giaquinta D Manag Care Interface; 2003 Jun; 16(6):49-50. PubMed ID: 12841076 [No Abstract] [Full Text] [Related]
9. The OTC drug approval process. The ACG Committee on FDA-Related Matters. American College of Gastroenterology. Fredd SB Am J Gastroenterol; 1990 Jan; 85(1):12-4. PubMed ID: 2296959 [TBL] [Abstract][Full Text] [Related]
10. Regulation of topical antimicrobials: history, status and future perspective. Bruch MK; Larson E Infect Control Hosp Epidemiol; 1989 Nov; 10(11):505-8. PubMed ID: 2685100 [TBL] [Abstract][Full Text] [Related]
11. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs. Strong M Food Drug Law J; 1999; 54(3):463-87. PubMed ID: 11797710 [No Abstract] [Full Text] [Related]
12. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health. Spencer HM Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546 [No Abstract] [Full Text] [Related]
13. Ugly wait at the counter. Insurer pushes to make allergy drugs nonprescription. Benko LB Mod Healthc; 2001 Aug; 31(32):22-3. PubMed ID: 11507861 [No Abstract] [Full Text] [Related]
14. Plan BTC: the case for a third class of drugs in the United States. Healey D Food Drug Law J; 2008; 63(1):375-89. PubMed ID: 18561465 [No Abstract] [Full Text] [Related]
15. Ophthalmic drug products for over-the-counter human use; final monograph; technical amendment. Final rule; technical amendment. Food and Drug Administration, HHS Fed Regist; 2003 Feb; 68(33):7919-21. PubMed ID: 12593411 [TBL] [Abstract][Full Text] [Related]
16. Prescription to over-the-counter switch: a regulatory perspective. Juhl RP Clin Ther; 1998; 20 Suppl C():C111-7. PubMed ID: 9915097 [TBL] [Abstract][Full Text] [Related]
17. Need a new drug? Gorman C Time; 1995 Jul; 146(5):52. PubMed ID: 10144386 [No Abstract] [Full Text] [Related]
18. An early historical perspective on the FDA's regulation of OTC drugs. Bruch MK; Larson E Infect Control Hosp Epidemiol; 1989 Nov; 10(11):527-8. PubMed ID: 2685103 [No Abstract] [Full Text] [Related]
19. The FDA takes action against unapproved drugs. Meadows M FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837 [TBL] [Abstract][Full Text] [Related]